

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for treating a B-cell disorder in a horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat, consisting of administering to the horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat having said disorder a therapeutic composition consisting of ~~at least one anti-CD20, anti-CD74 or~~ an anti-HLA-DR antibody component and a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, each in a pharmaceutically acceptable carrier.

2. (Original) The method of claim 1, wherein said antibody component is a naked antibody.

3. (Original) The method of claim 1, wherein said antibody component is an immunoconjugate.

4. Canceled.

5. (Original) The method of claim 3, wherein said immunoconjugate is a radiolabeled immunoconjugate.

6. (Original) The method of claim 3, wherein said immunoconjugate comprises a cytokine.

7. (Original) The method of claim 3, wherein said immunoconjugate comprises a drug or toxin.

8. (Original) The method of claim 1, wherein said antibody component is part of a fusion protein.

9. (Currently amended) ~~The method of claim 1—~~ A method for treating a B-cell disorder in a horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat, consisting of administering to the horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat having said disorder a therapeutic composition consisting of an anti-HLA-DR antibody component and a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, each in a pharmaceutically acceptable carrier, wherein said B-cell disorder is a malignancy.

10. (Previously presented) The method of claim 1, wherein said B-cell disorder is an autoimmune disease.

11-13. Canceled.

14. (Original) The method of claim 1, additionally comprising administering a cytokine.

15. (Original) The method of claim 1, additionally comprising administering a chemotherapeutic agent.

16. (Previously presented) The method of claim 1, wherein said therapeutic composition is administered to a companion animal.

17. (Original) The method of claim 16, wherein said companion animal is a dog or a cat.

18. (Previously presented) The method of claim 1, wherein said therapeutic composition is administered to a horse.

19-24. Canceled.

25. (Previously presented) The method of claim 1, wherein said therapeutic composition comprises a combination of two or more naked antibodies against different epitopes of the same antigen or against different antigens associated with one cell type.

26. (Previously presented) The method of claim 1, wherein said therapeutic composition comprises a combination of a naked antibody and a radiolabelled immunoconjugate.

27. (Previously presented) The method of claim 1, wherein said therapeutic composition comprises a combination of a naked antibody and a toxin immunoconjugate.

28. (Original) The method of claim 27, wherein said toxin immunoconjugate comprises an RNase.

29. (Original) The method of claim 28, wherein said RNase is a recombinant RNase.

30-31. Canceled.

32. (Original) The method of claim 1, wherein the antibody component comprises a multispecific antibody.

33. (Original) The method of claim 1, wherein the antibody component comprises a bispecific antibody.

34. (Previously presented) The method of claim 33, wherein said antibody component comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten with an attached therapeutic agent is administered after the antibody component is administered and has bound to the antigen or epitope.

35. (Original) The method of claim 34, wherein the therapeutic agent is a radionuclide.

36. (Original) The method of claim 34, wherein the therapeutic agent is a drug.

37. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of a chemotherapeutic agent and an antibody component labeled with a therapeutic radionuclide.

38-40. Canceled.

41. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of naked antibodies.

42. (Original) The method of claim 41, wherein said therapeutic composition comprises a fusion protein of said combination of antibodies.

43. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of naked antibodies and immunoconjugates.

44. (Previously presented) The method claim 1, wherein said therapeutic composition comprises a hybrid antibody that binds to more than one antigen.

45. Canceled.

46. (Original) The method of claim 1, additionally comprising administering radiation therapy.

47. Canceled.

48. (Original) The method of claim 1, additionally comprising administering an immunosuppressive agent.

49-51. Canceled.

52. (Previously presented) The method of claim 1, wherein said antibody component is a naked anti-HLA-DR antibody.

53. (Previously presented) The method of claim 10, wherein said autoimmune disease is selected from the group consisting of immune-mediated autoimmune hemolytic anemia, canine granulomatous meningoencephalitis, rheumatoid arthritis, chronic superficial keratitis, systemic lupus erythematosus, bullous pemphigoid, pemphigus, and thrombocytopenia.

54. (Currently amended) The method of claim ~~10~~ 9, wherein said malignancy is lymphoma.

55. (Previously presented) The method of claim 54, wherein said animal is a cat or a dog.

56. (Previously presented) The method of claim 10, wherein said autoimmune disease is autoimmune hemolytic anemia.

- 57. (New) The method of claim 54, wherein said lymphoma is a B-cell lymphoma.
- 58. (New) The method of claim 9, wherein said malignancy is a leukemia.
- 59. (New) The method of claim 54, wherein said lymphoma is a B-cell leukemia.
- 60. (New) A method for treating a B-cell disorder in a horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat, consisting of administering to the horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat having said disorder a therapeutic composition consisting of an anti-HLA-DR antibody component and, optionally, a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, each in a pharmaceutically acceptable carrier.
- 61. (New) The method of claim 60, wherein said anti-HLA-DR antibody is a naked antibody.
- 62. (New) The method of claim 60, wherein said B-cell disorder is a malignancy.
- 63. (New) The method of claim 62, wherein said anti-HLA-DR antibody is a naked antibody.